Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Daily News

More Than Half of All HF Patients Take 10 or More Meds

L.A. McKeown

October 20, 2020

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

L.A. McKeown

October 09, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

Shelley Wood

October 01, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Conference News ESC 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Michael O'Riordan

September 01, 2020

News Conference News ESC 2020

Dapagliflozin Wins in Patients With CKD

Todd Neale

August 31, 2020

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

News Daily News

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

Michael O'Riordan

August 13, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Race and Gender Bias May Sway Decisions in Advanced HF Care

L.A. McKeown

July 21, 2020

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

L.A. McKeown

March 20, 2020

News Daily News

COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say

Todd Neale

March 17, 2020

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Advertisement

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

More Than Half of All HF Patients Take 10 or More Meds

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

TCTMD’s Top 10 Most Popular Stories for September 2020

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Dapagliflozin Wins in Patients With CKD

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Race and Gender Bias May Sway Decisions in Advanced HF Care

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Missed Opportunities: Many HF Patients Not Tested for CAD

COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content